1. Home
  2. Age-Related Macular Degeneration (ARMD)

Age-Related Macular Degeneration (ARMD)
Symptoms, Doctors, Treatments, Advances & More

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

Age-Related Macular Degeneration (ARMD) Overview

  • Definition
  • Alternate Names
  • Causes
  • Symptoms
  • Treatments
  • Top Doctors
  • Support Groups
  • Prognosis
  • Complications
  • When To Seek Help
  • Preventions
  • Clinical Trials
  • Latest Advances
Save information for later
Sign Up

Learn About Age-Related Macular Degeneration (ARMD)

What is the definition of Age-Related Macular Degeneration (ARMD)?
Macular degeneration, also known as age-related macular degeneration (AMD), is the deterioration of the part of the eye (macula) that allows for seeing clearly in the center of the field of vision, as well as the ability to see straight ahead, and is the leading cause of central vision loss among older individuals over the age of 50. Macular degeneration has two types: 1) Dry macular degeneration, and 2) Wet macular degeneration. Dry macular degeneration, also known as Non-neovascular macular degeneration, is the most common type (90%) and gradually causes significant vision loss as the macular cells deteriorate, leading to blurry vision and blank spots in the center field of vision. Wet macular degeneration is the less common and more serious type (10%) and occurs when new blood vessels grow (choroidal neovascularization; CNV) beneath the retina that leak blood and fluid into the macula and cause scarring that leads to rapid vision loss. Age-related macular degeneration is more common in individuals of European descent.
What are the alternative names for Age-Related Macular Degeneration (ARMD)?
There are several alternative names for macular degeneration, including age-related macular degeneration (AMD), age-related maculopathy, and ARMD.
What are the different types of Age-Related Macular Degeneration (ARMD)?

Common conditions include: Geographic Atrophy

What are the causes of Age-Related Macular Degeneration (ARMD)?
Researchers believe that the causes of macular degeneration are a combination of genetic and environmental factors. While several types of genes and genetic mutations possibly contribute to the development of the disease, aging is the main risk factor for developing the macular degeneration. Other risk factors for developing macular degeneration include being Caucasian, having high blood pressure (hypertension), obesity, eating a diet high in fat with a high glycemic index or low in antioxidants and zinc, smoking cigarettes, having cardiovascular disease, such as high blood cholesterol levels, exposure to ultraviolet (UV) rays from sunlight, and having a family history of age-related macular degeneration.
What are the symptoms of Age-Related Macular Degeneration (ARMD)?
While early macular degeneration may have no symptoms, symptoms of later macular degeneration may include blurry vision and the gradual or rapid loss (depending on the type) of the ability to see straight ahead and to have fine, detailed vision; slower vision adjustment to darkness (dark adaptation) and dim light; the decreased ability to recognize friends; visual hallucinations (Charles Bonnet Syndrome); and the appearance of fluffy, yellow-white spots (drusen) on the macula of the eye. An early symptom of wet age-related macular degeneration may include the seeing straight lines or edges that appear crooked.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Age-Related Macular Degeneration (ARMD)?
While there is no cure for either dry or wet age-related macular degeneration, treatment depends on the type and may help to slow progression of the disease. Treatments for dry age-related macular degeneration focus on slowing progression of the disease and prevention of the disease in the other eye and includes vitamin regimens, such as 500 milligrams of Vitamin C; 400 International Units of Vitamin E; 15 milligrams of beta-carotene (25,000 International Units of Vitamin A) or 10 milligrams of lutein and 2 mg of zeaxanthin for smokers; 80 milligrams of zinc oxide; and 2 milligrams of copper (cupric oxide); and eating a diet high in leafy vegetables and nuts. Treatments for wet age-related macular degeneration also focus on slowing the progression of the disease and include the vitamin regimen listed above; anti-vascular endothelial growth factor (anti-VEGF) therapy, which are drugs given by injection into the eye (intravitreal) that stop the growth of abnormal blood vessels and leakage of blood into the macula, and which may possibly help to restore lost vision; and laser and photodynamic therapy, using a light-activated drug, verteporfin (Visudyne), to seal the leaky blood vessels. For macular degeneration that is progressing and/or threatening vision, intravitreal (in the eye) injections of the drugs, bevacizumab, aflibercept, or ranibizumab, may be administered with or without laser therapy. In addition the above treatments, patients with age-related macular degeneration who have lost vision may need to use low-vision aids, such as optical devices, magnifying spectacles, handheld magnifiers, stand magnifiers, large type on computers and/or talking computers, large print books and newspapers, high-contrast watches, enhanced lighting, and visual rehabilitation. Rarely, in some select patients, an implantable miniature telescope may be implanted into the eye to help improve vision and quality of life.
Who are the top Age-Related Macular Degeneration (ARMD) Local Doctors?
Philip J. Rosenfeld
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Philip J. Rosenfeld
Ophthalmology
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Philip J. Rosenfeld
Ophthalmology
Referral may be required
900 Northwest 17th Street, 
Miami, FL 
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Philip Rosenfeld is an Ophthalmologist practicing medicine in Miami, Florida. Dr. Rosenfeld is rated as an Elite provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Carotid Artery Surgery, and Vitrectomy. Dr. Rosenfeld is currently accepting new patients.

Jaclyn L. Kovach
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Jaclyn L. Kovach
Ophthalmology
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Jaclyn L. Kovach
Ophthalmology
Referral may be required
3880 Tamiami Trail North, 
Naples, FL 
305-243-2020
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jaclyn Kovach is an Ophthalmologist practicing medicine in Naples, Florida. Dr. Kovach is rated as an Elite provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Central Serous Chorioretinopathy, and Hormone Replacement Therapy (HRT). Dr. Kovach is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Harry W. Flynn
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Harry W. Flynn
Ophthalmology
Elite in Age-Related Macular Degeneration (ARMD)
Dr. Harry W. Flynn
Ophthalmology
Referral may be required
900 Northwest 17th Street, 
Miami, FL 
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Harry Flynn is an Ophthalmologist practicing medicine in Miami, Florida. Dr. Flynn is rated as an Elite provider by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Endophthalmitis, Retinal Detachment, Interstitial Keratitis, Vitrectomy, and Cataract Removal. Dr. Flynn is currently accepting new patients.

View All Doctors
What are the support groups for Age-Related Macular Degeneration (ARMD)?
There are several online, local, national, and international support groups for macular degeneration, including the following: American Macular Degeneration Foundation - https://www.macular.org/ Macular Society - https://www.macularsociety.org/local-support-groups MD Support - http://www.mdsupport.org/support/
What is the outlook (prognosis) for Age-Related Macular Degeneration (ARMD)?
The outcomes (prognosis) for macular degeneration vary. While age-related macular degeneration is a lifelong disease, patients with early age-related macular degeneration who are treated rarely ever develop advanced vision loss and have the ability to lead fairly normal lives.
What are the possible complications of Age-Related Macular Degeneration (ARMD)?
Possible complications of macular degeneration include visual hallucinations (Charles Bonnet Syndrome), vision loss, and blindness. Treatment-related complications for macular degeneration may also rarely occur, such as eye irritation or discharge or seeing spots or floaters.
When should I contact a medical professional for Age-Related Macular Degeneration (ARMD)?
If you experience any changes in your vision, especially those that occur suddenly and/or interfere with reading or recognizing other people, make an appointment with your doctor as soon as possible. If you notice that straight lines or edges start to look wavy, see an ophthalmologist (eye doctor) immediately, as this symptom can indicate progressed, late stage age-related macular degeneration.
How do I prevent Age-Related Macular Degeneration (ARMD)?
While there is no know method to prevent macular degeneration, the risk of developing the disease can be decreased by quitting smoking, eating a diet high in green leafy vegetables, fruits, fish, and nuts, exercising regularly, and maintaining healthy blood pressure and blood cholesterol levels. If you have a family history of age-related macular degeneration, undergoing regular eye exams is especially important to allow for early treatment, if necessary.
What are the latest Age-Related Macular Degeneration (ARMD) Clinical Trials?
A Phase I, Multicenter, Open-Label, Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 Administered by Intravitreal Injection as Monotherapy and in Combination With Faricimab in Patients With Diabetic Macular Edema
A Phase I, Multicenter, Open-Label, Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 Administered by Intravitreal Injection as Monotherapy and in Combination With Faricimab in Patients With Diabetic Macular Edema
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: The purpose of this study is to evaluate the safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of multiple doses of RO7823653 in participants with DME, administered by intravitreal (IVT) injection as monotherapy and co-administered with faricimab.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Randomized, Dose-Masked Study of Intravitreal EYE103 in Participants With Neovascular Age-Related Macular Degeneration (NVAMD) or Macular Edema Following Branch Retinal Vein Occlusion (BRVO)
A Phase 2 Randomized, Dose-Masked Study of Intravitreal EYE103 in Participants With Neovascular Age-Related Macular Degeneration (NVAMD) or Macular Edema Following Branch Retinal Vein Occlusion (BRVO)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of EYE103 via IVT or a high dose of EYE103 via IVT. 40 participants will be...

View All Clinical Trials
What are the Latest Advances for Age-Related Macular Degeneration (ARMD)?
Retinal anti-VEGF treatment now, and what next? From loading doses to long-game thinking.
Retinal anti-VEGF treatment now, and what next? From loading doses to long-game thinking.
Journal: Expert opinion on pharmacotherapy
Published: June 24, 2026
Smartphone-based offline AI for multi-disease retinal screening: Real-world accuracy.
Smartphone-based offline AI for multi-disease retinal screening: Real-world accuracy.
Journal: European journal of ophthalmology
Published: June 24, 2026
Tired of the same old research?
Check Latest Advances
Association Between the Social Deprivation Index and Neovascular Age-Related Macular Degeneration Outcomes.
Association Between the Social Deprivation Index and Neovascular Age-Related Macular Degeneration Outcomes.
Journal: Journal of vitreoretinal diseases
Published: June 23, 2026
View All Latest Advances
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved